Hirva Mamdani

Karmanos Cancer Institute

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2021

Collaborators (4)

Ari VanderWalde

Global Head of Clinical Trials

UNITED STATES

View details

Ira Winer

Associate Professor

Wayne State University

UNITED STATES

View details

Fulvio Lonardo

Wright State University

UNITED STATES

View details

Stephen Williamson

Professor Emeritus

UNIVERSITY OF KANSAS SCHOOL OF MEDICINE

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hirva Mamdani

Research Interests

Explore related searches

Contact this professor

Articles (10)

Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial

Health disparities among cancer patients who received molecular testing for biomarker-directed therapy

Evaluation of the Immune Response within the Tumor Microenvironment in African American and Non-Hispanic White Patients with Non–Small Cell Lung Cancer

A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.1

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.1

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2

Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer

Collaborators (4)

Ari VanderWalde

Ira Winer

Fulvio Lonardo

Stephen Williamson

Make your next move.